Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges

Li, Shangyong; Zhang, Hui; Chen, Kaiwei; Jin, Man-Wen; Vu, Son Hai; Jung, Samil; He, Ningning; Zhang, Zheng; Lee, Myeong‐Sok

doi:10.1080/10717544.2022.2058646

Cited by 84 publications

(38 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric cancer (GC) is the most common malignant tumor of the digestive system [ 1 ]. Despite the fact that there has been considerable advancement in terms of treatments, it remains the second leading cause of mortality due to cancer [ 2 , 3 ]. In China, both the incidence and mortality rates of GC have been on the rise [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer

Huang

Zheng

et al. 2022

Disease Markers

View full text Add to dashboard Cite

The prognosis of gastric cancer (GC) is difficult to predict due to the disease’s complex genetic and phenotypic characteristics. MUC16 has been reported to be involved in the progression of several tumors. In this study, we aimed to explore whether MUC16 mutation had any impact on the prognosis or treatments of GC patients. Additionally, this analysis uncovered possible critical pathways related with these systems. On the cBioPortal, we were able to locate the pertinent data of patients with MUC16 mutations. And then, GSEA analysis identified differences in mRNA levels between mutant and wild-type MUC16 patients in terms of biological function annotation and pathways. The KEGG and GO analyses were also performed using the differentially expressed genes (DEGs). There were 139 individuals with GC who had the MUC16 mutation, which accounts for 32 percent, and the remaining patients had the MUC16 wild type. Survival assays revealed that patients with the MUC16 mutation had longer overall survival and disease-free survival. GSEA analysis revealed that cell cycle, cysteine and methionine metabolism, Huntington’s disease, one carbon pool by folate, pyrimidine metabolism, pyruvate metabolism, RNA degradation, spliceosome, and valine leucine and isoleucine degradation were distinctly enriched in patients with MUC16 mutation type. Moreover, we identified 323 DEGs. Among them, 162 genes were upregulated, and 161 genes were downregulated. GO and KEGG assays indicated DEGs as enriched in pancreatic secretion, neuroactive ligand-receptor interaction, protein digestion and absorption, fat digestion and absorption, and glycerolipid metabolism. Overall, our data revealed that the MUC16 mutation in GC may affect the development of patients by altering several genes and pathways, indicating the importance of MUC16 mutation in the treatments of GC on an individual basis.

show abstract

Section: Introductionmentioning

confidence: 99%

Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer

Huang

Zheng

et al. 2022

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Chitosan (CS), as one of the most abundant natural macromolecules, has received considerable attention for its high biosafety, low immunogenicity, excellent biocompatibility, admirable biodegradability, and versatile biological activities [1][2][3][4][5][6][7][8][9]. In addition, CS is the only natural cationic polymer.…”

Section: Introductionmentioning

confidence: 99%

Dually Responsive Nanoparticles for Drug Delivery Based on Quaternized Chitosan

Qiao

Jiang

Fang

et al. 2022

IJMS

View full text Add to dashboard Cite

In this work, we report the fabrication and functional demonstration of a kind of dually responsive nanoparticles (NPs) as a potential drug delivery vector. The pH value, corresponding to the acidic microenvironment at the tumor site, and mannitol, to the extracellular trigger agent, were employed as the dually responsive factors. The function of dual responses was achieved by breaking the dynamic covalent bonds between phenylboronic acid (PBA) groups and diols at low pH value (pH 5.0) and/or under the administration of mannitol, which triggered the decomposition of the complex NPs and the concomitant release of anticancer drug of doxorubicin (DOX) loaded inside the NPs. The NPs were composed of modified chitosan (PQCS) with quaternary ammonium and PBA groups on the side chains, heparin (Hep), and poly(vinyl alcohol) (PVA), in which quaternary ammonium groups offer the positive charge for the cell-internalization of NPs, PBA groups serve for the formation of dynamic bonds in responding to pH change and mannitol addition, PVA furnishes the NPs with diol groups for the interaction with PBA groups and the formation of dynamic NPS, and Hep plays the roles of reducing the cytotoxicity of highly positively-charged chitosan and forming of complex NPs for DOX up-loading. A three-step fabrication process of drug-loaded NPs was described, and the characterization results were comprehensively demonstrated. The sustained drug release from the drug-loaded NPs displayed obvious pH and mannitol dependence. More specifically, the cumulative DOX release was increased more than 1.5-fold at pH 5.0 with 20 mg mL−1 mannitol. Furthermore, the nanoparticles were manifested with effective antitumor efficient and apparently enhanced cytotoxicity in response to the acidic pH value and/or mannitol.

show abstract

“…Given the tailored properties of controlled release of sodium alginate (ALG), it can protect drugs from degradation in the acidic environment and, more importantly, can enhance the oral bioavailability of drugs, thereby providing an ideal candidate for the enteric coating of nanoparticles [ 23 , 24 ]. Ascribe to the strong electrostatic interaction between alginate and chitosan, the nanoparticles are capable of shrinking and gelling at low pH, aiming to protect the peptide from the aggressive stomach environment [ 25 ]. In general, an oral administration carrier based on alginate-coated chitosan nanoparticles, with enhanced permeability, excellent stability, and high drug payload, can be engineered to orally deliver a host of therapeutic peptides and proteins such as exenatide, presenting extensive application prospects [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats

Yang

Lin

et al. 2022

Polymers

View full text Add to dashboard Cite

Oral delivery of therapeutic peptides has been a daunting challenge due to poor transport across the tight junctions and susceptibility to enzymatic degradation in the gastrointestinal tract. Numerous advancement in nanomedicine has been made for the effective delivery of protein and peptide. Owing to the superior performance of chitosan in opening intercellular tight junctions of epithelium and excellent mucoadhesive properties, chitosan-based nanocarriers have recently garnered considerable attention, which was formulated in this paper to orally deliver the GLP-1 drug (Exenatide). Against this backdrop, we used chitosan (CS) polymers to encapsulate the exenatide, sodium tripolyphosphate (TPP) as the cross-linking agent and coated the exterior with sodium alginate (ALG) to impart the stability in an acidic environment. The chitosan/alginate nanoparticles (CS-TPP-ALG) functioned as a protective exenatide carrier, realized efficient cellular uptake and controlled release, leading to a steady hypoglycemic effect and a good oral bioavailability in vivo. Trimethyl chitosan (TMC), a chitosan derivative with stronger positive electrical properties was additionally selected as a substitute for chitosan to construct the TMC-TPP-ALG nanoparticle, and its oral peptide delivery capacity was explored in terms of both characterization and pharmacodynamics studies. Overall, our study demonstrated that functional chitosan/alginate nanoparticles can protect proteins from enzymatic degradation and enhance oral absorption, which presents important research value and application prospects.

show abstract

Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges

Cited by 84 publications

References 67 publications

Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer

Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer

Dually Responsive Nanoparticles for Drug Delivery Based on Quaternized Chitosan

Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats

Contact Info

Product

Resources

About